A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.
A health-economic evaluation of aspirin: primary prevention and cardiovascular disease.
复制标题
阿司匹林的健康经济评估：初级预防和心血管疾病。
DOI：
10.2169/internalmedicine.46.0007
复制
发表时间：
2007
影响因子：
1.2
通讯作者：
K. Saku
中科院分区：
文献类型：
--
作者：
T. Sakai;K. Saku
最初的心血管疾病（CVD）一级预防指南于1997年出版，旨在帮助医疗保健专业人员及其未患有冠状动脉疾病或其他动脉粥样硬化疾病的患者（1）。2002年更新的《指南》承认自1997年以来在初级预防领域取得的一些进展。研究继续完善关于检测和管理既定风险因素的建议，包括曾经被认为有希望的干预措施（如抗氧化维生素）的安全性和有效性的证据（2）。这反过来又刺激了针对特定人口统计学群体（如女性）、个体风险因素（如糖尿病、吸烟）和卒中一级预防的大量额外指南。在所有这些指南中，越来越强调进一步按风险水平对患者进行分层，并将干预强度与心血管疾病事件的危害相匹配（3）。因此，2002年对《初级预防指南》的更新是为了纳入自最初的《指南》核准以来制定的其他准则和共识声明。虽然阿司匹林对已知心血管疾病患者的益处已得到充分证实（4），但阿司匹林是否能降低无已知心血管疾病患者的心血管疾病风险的问题仍存在争议。2006年，确定了6项试验，共95，456人; 3项试验仅包括男性，1项仅包括女性，2项包括男女（5），以确定阿司匹林治疗在心血管疾病一级预防中的益处和风险。
The initial Guide to the Primary Prevention of cardiovascular disease (CVD) was published in 1997 as an aid to healthcare professionals and their patients without established coronary artery disease or other atherosclerotic diseases (1). The 2002 update of the Guide acknowledges a number of advances in the field of primary prevention since 1997. Research continues to refine the recommendations on detection and management of established risk factors, including evidence against the safety and efficacy of interventions once thought promising (eg, antioxidant vitamins) (2). This, in turn, has stimulated a large number of additional guidelines for specific demographic groups (eg, women), on individual risk factors (eg, diabetes, smoking), and for the primary prevention of stroke. In all of these guidelines, there is an increasing emphasis on further stratifying patients by the level of risk and matching the intensity of intervention to the hazard for cardiovascular disease events (3). Therefore, the 2002 update of the Primary Prevention Guide serves to integrate other guidelines and consensus statements developed since the initial Guide’s approval. Although the benefit of aspirin for patients with known cardiovascular disease is well established (4), the question of whether or not aspirin reduces the risk for cardiovascular disease in persons without known cardiovascular disease is controversial. In 2006, six trials with a total of 95,456 individuals were identified; 3 trials included only men, 1 included only women, and 2 included both sexes (5) to determine the benefits and risks of aspirin treatment in the primary prevention of cardiovascular disease.
影响因子：
158.5
作者：
HENNEKENS, CH
通讯作者：
HENNEKENS, CH